LNW:ASXLight & Wonder, Inc. Shs Chess Depository Interests Repr 1 Sh Analysis
Data as of 2026-03-14 - not real-time
A$118.20
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Light & Wonder is trading around AUD 118, hugging its recent support level while technical gauges point to a short‑term oversold condition – the 14‑day RSI sits near 28 and the MACD histogram is negative, suggesting further downside pressure. However, the company posted solid top‑line growth (≈12% YoY revenue increase) and a 27% jump in EPS for FY 2025, backed by a 29% rise in EBITDA and aggressive share‑buybacks, which have helped sustain analyst sentiment at a "Buy" consensus.
Despite these positives, the stock appears markedly overvalued: the DCF‑derived fair value of roughly AUD 73 is well below the current price, and valuation multiples (PE ≈26×, PB ≈26×) are among the highest in the consumer‑cyclical space. Coupled with a 30‑day volatility near 54% and a high‑beta exposure to the gambling sector, the upside appears limited while downside risks from regulatory scrutiny and a hefty debt load remain pronounced.
Despite these positives, the stock appears markedly overvalued: the DCF‑derived fair value of roughly AUD 73 is well below the current price, and valuation multiples (PE ≈26×, PB ≈26×) are among the highest in the consumer‑cyclical space. Coupled with a 30‑day volatility near 54% and a high‑beta exposure to the gambling sector, the upside appears limited while downside risks from regulatory scrutiny and a hefty debt load remain pronounced.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- RSI below 30 indicating oversold conditions
- Price near established support level
- Strong analyst buy consensus despite recent pullback
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Robust earnings growth and cash flow generation
- Persistently high valuation multiples
- Elevated sector volatility and regulatory exposure
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High ROE and operating margins support sustainable profitability
- Excessive debt‑to‑equity ratio raises balance‑sheet concerns
- Long‑term industry cyclicality and competitive pressures
Key Metrics & Analysis
Financial Health
Revenue Growth11.70%
Profit Margin8.33%
P/E Ratio25.9
ROE62.66%
ROA9.49%
Debt/Equity2126.53
P/B Ratio26.3
Op. Cash FlowA$794.0M
Free Cash FlowA$491.5M
Technical Analysis
TrendNeutral
RSI28.4
SupportA$118.20
ResistanceA$149.94
MA 20A$131.99
MA 50A$152.28
MA 200A$141.16
MACDBearish
VolumeStable
Fear & Greed Index72.88
Valuation
Fair ValueA$72.91
Target PriceA$196.54
Upside/Downside66.27%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.93
Volatility53.89%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.